Company intelligence / Profile preview

Wuxi Jiyu Shanhe Pharmaceutical

Wuxi, Jiangsu, China

Ownership: Private
Development stage: Other

Overview

Wuxi Jiyu Shanhe Pharmaceutical has approved products in neurology, psychiatry, and respiratory/pharyngeal diseases, plus ongoing clinical development in higher-tech oncology (liposome injection for solid tumors). Herbal compounds and generics dominate commercial output, with newer modalities (e.g. liposomes) under clinical trial. Clinical trial results and pipeline data point to small molecule and herbal drug approvals as well as innovative cancer therapy in early clinical stages

Therapeutic areas: OphthalmologyPsychiatryInfectious DiseasesOncologyNeurology
Modalities: Herbal medicineSmall moleculeLiposome
Industry: Biotech

Partnerships

MedicilonJemincare Group

Beyond the preview

Go deeper on Wuxi Jiyu Shanhe Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Wuxi Jiyu Shanhe Pharmaceutical.

Explore the full profile